[go: up one dir, main page]

AU2001243219A1 - Methods of prevention and treatment of asthma, and allergic conditions - Google Patents

Methods of prevention and treatment of asthma, and allergic conditions

Info

Publication number
AU2001243219A1
AU2001243219A1 AU2001243219A AU4321901A AU2001243219A1 AU 2001243219 A1 AU2001243219 A1 AU 2001243219A1 AU 2001243219 A AU2001243219 A AU 2001243219A AU 4321901 A AU4321901 A AU 4321901A AU 2001243219 A1 AU2001243219 A1 AU 2001243219A1
Authority
AU
Australia
Prior art keywords
asthma
prevention
treatment
methods
allergic conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001243219A
Inventor
Simon Skurkovich
Boris Sukurkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Biotherapy Concepts Inc
Original Assignee
Advanced Biotherapy Concepts Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biotherapy Concepts Inc filed Critical Advanced Biotherapy Concepts Inc
Publication of AU2001243219A1 publication Critical patent/AU2001243219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001243219A 2000-02-24 2001-02-23 Methods of prevention and treatment of asthma, and allergic conditions Abandoned AU2001243219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/511,972 US6846486B1 (en) 2000-02-24 2000-02-24 Method of treating allergy by administering an anti-histamine antibody
US09511972 2000-02-24
PCT/US2001/005660 WO2001062287A1 (en) 2000-02-24 2001-02-23 Methods of prevention and treatment of asthma, and allergic conditions

Publications (1)

Publication Number Publication Date
AU2001243219A1 true AU2001243219A1 (en) 2001-09-03

Family

ID=24037164

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001243219A Abandoned AU2001243219A1 (en) 2000-02-24 2001-02-23 Methods of prevention and treatment of asthma, and allergic conditions

Country Status (3)

Country Link
US (4) US6846486B1 (en)
AU (1) AU2001243219A1 (en)
WO (1) WO2001062287A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (en) 1998-12-14 2007-07-01 Genetics Institute, Llc CHAIN OF THE CYTOKIN RECEIVER.
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP2236156A3 (en) * 2001-01-09 2011-01-05 Baylor Research Institute Methods for treating and diagnosing Psoriasis
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2469459C (en) * 2001-12-07 2011-10-18 University Of Wyoming Methods and compositions for the diagnosis of asthma
WO2003082349A1 (en) * 2002-03-25 2003-10-09 Mercia Pharma, Llc Treatment methods for eotaxin mediated inflammatory conditions
MXPA04009418A (en) * 2002-03-29 2005-06-08 Schering Corp Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same.
JP2006503018A (en) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド vaccine
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2007525436A (en) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド Methods and compositions for treating and preventing inflammatory conditions
US7613153B2 (en) * 2003-11-06 2009-11-03 Interdigital Technology Corporation Access points with selective communication rate and scheduling control and related methods for wireless local area networks (WLANs)
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
NZ554065A (en) * 2004-10-07 2010-12-24 Univ Zuerich Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis
CA2597265C (en) * 2005-02-10 2015-03-24 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CA2657763C (en) 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
SE532249C2 (en) * 2006-11-13 2009-11-24 Theravac Pharmaceuticals Ab New formulations of IL-18 for the treatment of various inflammatory diseases by vaccination
SE532250C2 (en) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab New formulations of IL-33 for the treatment of inflammatory conditions with a strong TH2 component by vaccination
DE112008003232T5 (en) * 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2279207B1 (en) * 2008-05-07 2015-09-09 Argos Therapeutics, Inc. Humanized antibodies against human interferon-alpha
RU2011143776A (en) * 2009-03-30 2013-05-10 Протаб Лтд. PROTEIN ASSOCIATED WITH Adenylyl cyclase (CAP1) AND USE IT AS A TARGET FOR IMMUNOMODULATION
CN102573886A (en) * 2009-09-17 2012-07-11 相互制药公司 Method of treating asthma with antiviral agents
CA3059731A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
US12428466B2 (en) 2018-10-25 2025-09-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
KR102121122B1 (en) * 2018-11-01 2020-06-09 전북대학교산학협력단 Peptides that specifically bind histamine and their use
CN111518211B (en) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 Pharmaceutical application of human interleukin 4receptor alpha monoclonal antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
DE69123979T2 (en) 1990-10-12 1997-04-30 Max Planck Gesellschaft MODIFIED RIBOZYMS
US5510339A (en) * 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
CA2160583A1 (en) 1993-04-16 1994-10-27 Stanley A. Plotkin Recombinant cytomegalovirus vaccine
AU2195395A (en) 1994-03-28 1995-10-17 United Biomedical Inc. Synthetic peptide based immunogens for the treatment of allergy
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody

Also Published As

Publication number Publication date
US20050013800A1 (en) 2005-01-20
WO2001062287A1 (en) 2001-08-30
US20050013799A1 (en) 2005-01-20
US6846486B1 (en) 2005-01-25
US20050019305A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2002314466A1 (en) Withasol and methods of use
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002366338A1 (en) Catheter having improved curve retention and method of manufacture
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AUPR839001A0 (en) Dosage form, device and methods of treatment
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU6887101A (en) Copolymers and methods of treating prion-related diseases
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU2002366028A1 (en) Use of fk506 and analogues for treating allergic diseases
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002355432A1 (en) Kavalactone compositions and methods of use
AU2002219473A1 (en) Treatment of asthma and other lung conditions
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
AU2001253560A1 (en) Methods of treatment
AU2002246307A1 (en) Polyherbal composition for the treatment of bronchial asthma and the process
AUPR626001A0 (en) A method of treatment and/or prophylaxis